Abstract
A multidisciplinary team can help improve the outcomes of patients with any cancer, but particularly so for patients with soft-tissue sarcomas, as discussed at JADPRO Live. During this presentation, MD, PA, and NP colleagues from Moffitt Cancer Center reviewed the role of systemic therapy and emergence of targeted therapy for this subset of patients.
